In addition to the robust in vivo efficacy of PTPRZ1-TCR-T, we found universal targeting of HLA-A*02+ primary glioblastoma cell lines and malignant cells in IPTOs with a preference for stem-like SCCs and AC-like tumor cells. This evidence concerns the gene PTPRZ1 and glioblastoma.